Capricor Therapeutics (CAPR) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Capricor Therapeutics (CAPR) PT Raised to $25 at Ladenburg Thalmann
May 14, 2024 6:46 AM EDTLadenburg Thalmann analyst Aydin Huseynov raised the price target on Capricor Therapeutics (NASDAQ: CAPR) to $25.00 (from $24.00) while maintaining a Buy rating.
The analyst comments "CAPR seems to have advanced in its regulatory negotiations with the FDA with possible rolling BLA... More
